SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Weller M,Muller B,Koch R,Bamberg M,Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003; 21: 32763284.
  • 2
    Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987996.
  • 3
    Mirimanoff RO,Gorlia T,Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006; 24: 25632569.
  • 4
    Curran WJJr,Scott CB,Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704710.
  • 5
    Scott CB,Scarantino C,Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998; 40: 5155.
  • 6
    Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003; 30: 1014.
  • 7
    Hauch H,Sajedi M,Wolff JEA. Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res. 2005; 25: 35853590.
  • 8
    Planting AST,Ardizzoni A,Estape J, et al. Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. Cancer Chemother Pharmacol. 1991; 28: 145146.
  • 9
    Belinsky SA,Dolan ME,White CM, et al. Cell specific differences in O6-methylguanine-DNA methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells. Carcinogenesis. 1988; 9: 20532058.
  • 10
    Preuss I,Thust R,Kaina B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer. 1996; 65: 506512.
  • 11
    Wolff JE,Berrak S,Koontz Webb SE,Zhang M. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24,193 patients. J Neurooncol. 2008; 88: 5763.
  • 12
    Wasserfallen JB,Ostermann S,Pica A, et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004; 101: 20982105.
  • 13
    Dooms CA,Lievens YN,Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Resp J. 2006; 27: 895901.
  • 14
    Wasserfallen JB,Ostermann S,Leyvraz S,Stupp R. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro-Oncol. 2005; 7: 189195.
  • 15
    Hegi ME,Diserens A-C,Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 9971003.
  • 16
    Anda T,Shabani HK,Tsunoda K, et al. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res. 2003; 25: 241248.
  • 17
    Kamiryo T,Tada K,Shiraishi S, et al. Correlation between promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery. 2004; 54: 349357.